First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 25, 2019

Primary Completion Date

September 26, 2019

Study Completion Date

September 26, 2019

Conditions

OverweightHealthy Subjects

Interventions

DRUG

SAR441255

"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"

DRUG

placebo

"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"

Trial Locations (1)

Investigational site number 8400001, Knoxville